2009
Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market
Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market. The American Journal Of Drug And Alcohol Abuse 2009, 35: 68-72. PMID: 19212931, PMCID: PMC2791788, DOI: 10.1080/00952990802585406.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid withdrawal symptomsSyringe sharingWithdrawal symptomsSnowball recruitment techniquesLogistic regression analysisDiversion of buprenorphineLack of reductionEvidence-based approachPrimary outcomeBuprenorphine injectionOnly symptomBenzodiazepine useBenzodiazepine injectionStomach painBuprenorphineInjection doseRisk behaviorsSymptomsNaloxoneInjectionRegression analysisNLXDaily amountDose
2008
Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia
Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL. Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia. The American Journal Of Drug And Alcohol Abuse 2008, 34: 511-517. PMID: 18584580, DOI: 10.1080/00952990802122259.Peer-Reviewed Original ResearchConceptsBuprenorphine injectionBuprenorphine injectorsCase seriesSignificant adverse health consequencesProspective cohort studyPossible pharmacological interactionsAdverse health consequencesDiversion of buprenorphineCohort studyResultant symptomsPoor outcomeCase reportTreatment modalitiesPharmacological interactionsBuprenorphineEuphoric effectsHealth consequencesKuala LumpurMidazolamInjectionQualitative interviewsSymptoms